一种新的空间特异性蛋白质Fhl1调节了静脉移植的新极端增生
Chaoqun Wang1, Jiantao Chen1, Zicong Feng1
1Department of Cardiac Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Clinical and translational medicine
|December 6, 2024
概括
静脉移植中的新极端增生症 (NIH) 减少了四个半个LIM域蛋白1 (Fhl1). Fhl1作为一种保护因素,减轻炎症和扩散,为静脉移植失败提供潜在的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 血管外科 血管外科
- 分子医学是分子医学.
背景情况:
- 新阴极性增生 (NIH) 是冠状动脉疾病手术中静脉移植失败的主要原因.
- 目前针对NIH的方法不足,需要新的治疗策略.
研究的目的:
- 调查NIH背后的分子机制,并确定潜在的治疗点.
- 探索四个半个LIM域蛋白1 (Fhl1) 在NIH发展和进展中的作用.
主要方法:
- 建立了一种老鼠外静脉移植模型,以研究35天内的NIH进展.
- 利用空间转录学来分析新极端地区的基因表达.
- 在Fhl1淘汰赛大鼠和具有Fhl1过度表达的人类沙芬静脉中进行NIH评估.
主要成果:
- 新极端形成在移植后19天达到顶峰,来自外部α-SMA(+) 修复细胞.
- 在NIH期间,空间转录学揭示了在neointima中稳定的Fhl1表达.
- 在人体静脉移植中,Fhl1淘汰会加剧NIH,而在人体静脉移植中,Fhl1过度表达会抑制它.
结论:
- 新形成的修复细胞外部的移植在NIH中发挥着关键作用.
- Fhl1是对NIH的保护因子,具有抗炎和抗增殖作用.
- 在预防静脉移植失败方面,Fhl1是一个有前途的治疗标.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:10Mechanism of Angiogenesis
5.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.3K